Ribomic

Ribomic Equity Ratio

The Equity Ratio of Ribomic (4591.T) as of Oct 30, 2026 is 95.46 %. In the previous year, Equity Ratio was 95.54 % — a change of -0.08% (lower).

Equity Ratio

95.46 %

YoY

-0.08%

Last updated:

Equity Ratio of Ribomic is 2026 95.46 % . Equity Ratio of Ribomic was 2025 95.54 % . It decreases by -0.08% lower compared to the previous year.

The Ribomic Equity Ratio history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity Ratio
Date
Equity Ratio
Jan 1, 2019
57.73 JPY
Jan 1, 2020
96.08 JPY
Jan 1, 2021
98.09 JPY
Jan 1, 2022
94.74 JPY
Jan 1, 2023
95.65 JPY
Jan 1, 2024
95.61 JPY
Jan 1, 2025
95.54 JPY
Jan 1, 2026
95.46 JPY
The Ribomic Equity Ratio history
YEAREquity RatioYoY
95.46 %-0.08%
95.54 %-0.07%
95.61 %-0.05%
95.65 %+0.96%
94.74 %-3.41%
98.09 %+2.09%
96.08 %+66.44%
57.73 %-39.69%
95.71 %-2.05%
97.71 %+2.35%
95.47 %+0.05%
95.42 %+32.80%
71.85 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Ribomic Stock analysis

What does Ribomic do? Ribomic, Inc. engages in the research and development of molecular targeted drugs using Ribonucleic Acid (RNA) aptamers for therapeutic applications. Headquartered in Minato-Ku, Tokyo-To, the company utilizes its workforce of 25 full-time employees to drive its drug discovery operations, which are structured into self discovery and co-discovery divisions. This operational framework allows the firm to focus on advancing RNA aptamer technologies for medical use. The Self Drug Discovery division develops aptamers and licenses these results to pharmaceutical companies, generating revenue through intellectual property transfers. Meanwhile, the Co-Discovery division collaborates with alliance pharmaceutical companies researching aptamer pharmaceuticals. This segment earns research expenses paid by the alliance partners for the shared portion of the co-discovery business, creating a dual revenue stream based on licensing and collaborative research fees. Ribomic is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Ribomic stock

Equity Ratio of Ribomic is 95.46 % in 2026.

Equity Ratio of Ribomic changed from 95.54 % to 95.46 %, representing a -0.08% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Equity Ratio Ribomic since 2006 – with annual values, charts, and detailed analysis.

The equity ratio measures the proportion of total assets financed by shareholders' equity. Higher ratios indicate stronger financial independence and lower leverage.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Equity Ratio's Ribomic with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Ribomic

All Key Metrics — Ribomic